Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 13 · newest first

  1. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaBlood · 2016
  2. Treatment recommendations from the Eighth International Workshop on Waldenström’s MacroglobulinemiaBlood · 2016
  3. Managing renal complications in multiple myelomaExpert Review of Hematology · 2016
  4. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström MacroglobulinaemiaBritish Journal of Haematology · 2016
  5. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyLeukemia · 2016
  6. DNA damage, tumor mutational load and their impact on immune responses against cancerAnnals of Translational Medicine · 2016
  7. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)Leukemia · 2016
  8. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialJournal of Clinical Oncology · 2016
  9. Proteasome inhibitor associated thrombotic microangiopathyAmerican Journal of Hematology · 2016
  10. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsLeukemia & lymphoma/Leukemia and lymphoma · 2016
  11. The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic ProfilingPLoS ONE · 2016
  12. A review of the venous thrombotic issues associated with multiple myelomaExpert Review of Hematology · 2016
  13. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatmentBlood Cancer Journal · 2016
  14. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaBlood · 2016
  15. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)Leukemia & lymphoma/Leukemia and lymphoma · 2016
  16. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosisBlood · 2016
  17. The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016American Society of Clinical Oncology Educational Book · 2016
  18. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantationLeukemia & lymphoma/Leukemia and lymphoma · 2016
  19. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant settingOncotarget · 2016
  20. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myelomaHaematologica · 2016
  21. Emerging antibodies for the treatment of multiple myelomaExpert Opinion on Emerging Drugs · 2016
  22. Outcome of patients with nonmetastatic muscle‐invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin‐based chemotherapy and/or radiotherapy: a retrospective analysisCancer Medicine · 2016
  23. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentJournal of Clinical Oncology · 2016
  24. The Changing Landscape of Smoldering Multiple Myeloma: A European PerspectiveThe Oncologist · 2016
  25. Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myelomaLeukemia & lymphoma/Leukemia and lymphoma · 2016
  26. Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysisAmerican Journal of Hematology · 2016
  27. Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significanceLeukemia & lymphoma/Leukemia and lymphoma · 2016
  28. Cancer in pregnancy: disentangling treatment modalitiesESMO Open · 2016
  29. Evidence of a Redox‐Dependent Regulation of Immune Responses to Exercise‐Induced InflammationOxidative Medicine and Cellular Longevity · 2016
  30. Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive centerClinical and Experimental Gastroenterology · 2016
  31. The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016American Society of Clinical Oncology Educational Book · 2016
  32. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myelomaHaematologica · 2015
  33. A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple MyelomaBlood · 2015
  34. Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) TrialBlood · 2015
  35. Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group StudyBlood · 2015
  36. Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-upBlood · 2015
  37. Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple MyelomaBlood · 2015
  38. Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM)Blood · 2015
  39. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentBlood · 2015
  40. Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsyClinical Nephrology · 2015
  41. TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myelomaBritish Journal of Haematology · 2015
  42. Recent advances in the management of AL AmyloidosisBritish Journal of Haematology · 2015
  43. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple MyelomaBiology of Blood and Marrow Transplantation · 2015
  44. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related ComplicationsHaematologica · 2015
  45. Treatment of relapsed urothelial bladder cancer with vinflunineAnti-Cancer Drugs · 2015
  46. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 studyBlood · 2015
  47. Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapyHaematologica · 2015
  48. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple MyelomaJournal of Clinical Oncology · 2015
  49. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasoneHaematologica · 2015
  50. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupJournal of Clinical Oncology · 2015